Vironexis Biotherapeutics is pioneering AAV-delivered T-cell immunotherapy to transform cancer treatment
Vironexis Biotherapeutics is pioneering AAV-delivered T-cell immunotherapy to transform cancer treatment. Their TransJoin™ AAV Gene Therapy Platform aims to provide off-the-shelf, single-dose therapies that enhance the efficacy and safety of T-cell immunotherapy.
Vironexis Biotherapeutics is pioneering AAV-delivered T-cell immunotherapy to transform cancer treatment
Vironexis Biotherapeutics is pioneering AAV-delivered T-cell immunotherapy to transform cancer treatment. Their TransJoin™ AAV Gene Therapy Platform aims to provide off-the-shelf, single-dose therapies that enhance the efficacy and safety of T-cell immunotherapy.